Published in J Clin Oncol on December 01, 2000
Cancer immunotherapy comes of age. Nature (2011) 12.35
The cancer vaccine roller coaster. Nat Biotechnol (2009) 2.26
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest (2002) 2.09
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol (2011) 1.94
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother (2012) 1.82
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res (2011) 1.82
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One (2011) 1.38
Sipuleucel-T. Nat Rev Drug Discov (2010) 1.37
Cellular vaccine approaches. Cancer J (2010) 1.27
Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol (2013) 1.12
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother (2010) 1.12
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2011) 1.08
CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol (2008) 1.05
Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol (2010) 1.05
Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res (2009) 1.01
Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer (2005) 1.00
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother (2010) 0.99
Dendritic cells: a critical player in cancer therapy? J Immunother (2008) 0.99
Prostate cancer vaccines: Update on clinical development. Oncoimmunology (2013) 0.98
Immune Infiltration and Prostate Cancer. Front Oncol (2015) 0.98
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother (2011) 0.97
T-cell-inducing vaccines - what's the future. Immunology (2012) 0.95
Immunological monitoring of anticancer vaccines in clinical trials. Oncoimmunology (2013) 0.95
Immunotherapy for prostate cancer: an emerging treatment modality. Urol Clin North Am (2010) 0.94
A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res (2009) 0.94
From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines (2011) 0.94
Particle platforms for cancer immunotherapy. Int J Nanomedicine (2013) 0.93
Clinical evaluation of therapeutic cancer vaccines. Hum Vaccin Immunother (2013) 0.93
Management of high-risk localized prostate cancer. Adv Urol (2011) 0.93
Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother (2011) 0.92
Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol (2011) 0.91
Promising novel immunotherapies and combinations for prostate cancer. Future Oncol (2009) 0.91
Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Front Oncol (2014) 0.91
Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev (2014) 0.90
Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223. Ther Clin Risk Manag (2014) 0.90
Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy (2011) 0.90
Update on prostate cancer vaccines. Cancer J (2011) 0.88
Advances in preclinical investigation of prostate cancer gene therapy. Mol Ther (2007) 0.88
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Arch Med Sci (2012) 0.87
Recent developments in prostate cancer biomarker research: therapeutic implications. Br J Clin Pharmacol (2011) 0.86
Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host. Biology (Basel) (2013) 0.86
Vaccines as monotherapy and in combination therapy for prostate cancer. Clin Transl Sci (2010) 0.85
A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer (2015) 0.85
Immunotherapy for metastatic prostate cancer. Urol Oncol (2007) 0.85
Human prostatic acid phosphatase: structure, function and regulation. Int J Mol Sci (2013) 0.85
The role of immunotherapy in prostate cancer: an overview of current approaches in development. Rev Urol (2009) 0.85
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J (2013) 0.84
Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine (2011) 0.84
The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape. Front Immunol (2013) 0.83
Emerging therapies in castrate-resistant prostate cancer. Curr Urol Rep (2010) 0.83
Immunotherapy for advanced prostate cancer. Rev Urol (2007) 0.83
The current and emerging role of immunotherapy in prostate cancer. Clin Genitourin Cancer (2010) 0.83
Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer. Biomed Res Int (2015) 0.82
Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein. Br J Cancer (2004) 0.82
Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T (2011) 0.82
Dendritic cell-based immunotherapy. Cell Res (2016) 0.81
From bench to bedside: immunotherapy for prostate cancer. Biomed Res Int (2014) 0.81
Potential clinical applications for human pluripotent stem cell-derived blood components. Stem Cells Int (2011) 0.81
Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Expert Rev Vaccines (2011) 0.80
Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies. Ther Clin Risk Manag (2014) 0.80
Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol (2010) 0.80
Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015. Ther Clin Risk Manag (2008) 0.80
Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients. Br J Cancer (2004) 0.80
Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents. Drugs Aging (2014) 0.80
Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens. Cancer Immunol Immunother (2010) 0.80
Contemporary agents in the management of metastatic castration-resistant prostate cancer. Can Urol Assoc J (2016) 0.79
New therapeutics to treat castrate-resistant prostate cancer. ScientificWorldJournal (2013) 0.79
[Chemotherapy for prostate cancer]. Wien Klin Wochenschr (2008) 0.79
Research in castration-resistant prostate cancer: what does the future hold? Curr Oncol (2010) 0.79
The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus. Biomaterials (2013) 0.79
Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine. Hum Vaccin Immunother (2012) 0.79
Immune response to sipuleucel-T in prostate cancer. Cancers (Basel) (2012) 0.79
Emerging vaccine therapy approaches for prostate cancer. Rev Urol (2010) 0.78
Cytokine-based high log-scale expansion of functional human dendritic cells from cord-blood CD34-positive cells. Sci Rep (2011) 0.78
Immunobiology and immunotherapy in genitourinary malignancies. Ann Transl Med (2016) 0.78
Therapeutic cancer vaccines: the latest advancement in targeted therapy. Am J Ther (2012) 0.78
Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. Oncoimmunology (2015) 0.78
mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum Vaccin Immunother (2014) 0.78
Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. Onco Targets Ther (2011) 0.78
Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response. Stem Cells Transl Med (2013) 0.78
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Rev Urol (2003) 0.78
Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer. J Transl Med (2014) 0.77
Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy. J Hematol Oncol (2015) 0.77
Therapeutic prostate cancer vaccines: a review of the latest developments. Curr Opin Investig Drugs (2008) 0.77
Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Radiat Oncol (2016) 0.77
DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand? Genet Vaccines Ther (2012) 0.77
Dendritic cells as immunologic adjuvants for the treatment of cancer. J Clin Oncol (2000) 0.77
Evaluation of an α synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease. Hum Vaccin Immunother (2015) 0.77
Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists. Ther Adv Med Oncol (2011) 0.77
A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment. Oncol Rep (2015) 0.76
Immunotherapy and immune evasion in prostate cancer. Cancers (Basel) (2013) 0.76
The lack of predictors for rapid progression in prostate cancer patients receiving sipuleucel-T. Cancers (Basel) (2013) 0.76
CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. Oncoimmunology (2016) 0.76
Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. J Cancer (2011) 0.76
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective. Rev Urol (2003) 0.76
Sipuleucel-T for the Treatment of Patients With Metastatic Castrate-resistant Prostate Cancer: Considerations for Clinical Practice. Rev Urol (2015) 0.76
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene (1995) 2.84
Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res (2001) 2.64
Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res (1999) 2.02
The release of four mediators of immediate hypersensitivity from human leukemic basophils. J Immunol (1975) 1.92
The application of multiwavelet filterbanks to image processing. IEEE Trans Image Process (1999) 1.88
Cyclic AMP: a mitogenic signal for Swiss 3T3 cells. Proc Natl Acad Sci U S A (1981) 1.83
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res (2000) 1.81
Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol (1997) 1.80
Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene (1997) 1.78
Mechanisms of platelet aggregation by viridans group streptococci. Infect Immun (1987) 1.77
Multiple HLA class I-dependent cytotoxicities constitute the "non-HLA-restricted" response in infectious mononucleosis. Eur J Immunol (1987) 1.55
Novel effects of 1-O-hexadecyl-2-acyl-sn-glycero-3-phosphorycholine mediators on human leukocyte function: delineation of the specific roles of the acyl substituents. Biochem Biophys Res Commun (1980) 1.50
Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev (1994) 1.48
Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver. Ann Surg (1994) 1.46
Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol (2001) 1.46
Binding of viridans group streptococci to human platelets: a quantitative analysis. Infect Immun (1990) 1.41
Anaphylactoid reactions to vascular graft material presenting with vasodilation and subsequent disseminated intravascular coagulation. Anesthesiology (1989) 1.39
Specific binding of phospholipid platelet-activating factor by human platelets. J Immunol (1982) 1.33
Specific inhibition of the polymorphonuclear leukocyte chemotactic response to hydroxy-fatty acid metabolites of arachidonic acid by methyl ester derivatives. J Clin Invest (1979) 1.32
Alveolar macrophage lipoxygenase products of arachidonic acid: isolation and recognition as the predominant constituents of the neutrophil chemotactic activity elaborated by alveolar macrophages. Cell Immunol (1980) 1.28
Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces. Int Immunol (1990) 1.27
Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. Immunology (1983) 1.24
Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J (2002) 1.15
Evolution of the bioartificial liver: the need for randomized clinical trials. Am J Surg (1993) 1.11
The immunological generation of a platelet-activating factor and a platet-lytic factor in the rat. Immunology (1979) 1.07
Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate (1998) 1.07
Alterations in human leukocyte function induced by ingestion of eicosapentaenoic acid. J Clin Immunol (1986) 1.05
Modulation of the random migration of human platelets. J Clin Invest (1974) 1.05
Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol (2000) 1.03
Defective polymorphonuclear leukocyte chemotaxis in homosexual men with persistent lymph node syndrome. J Infect Dis (1984) 0.98
Immunologic release in the rat peritoneal cavity lipid chemotactic and chemokinetic factors for polymorphonuclear leukocytes. J Immunol (1978) 0.97
High density culture of mammalian cells with dynamic perfusion based on on-line oxygen uptake rate measurements. Cytotechnology (1994) 0.96
Formation of porcine hepatocyte spheroids for use in a bioartificial liver. Cell Transplant (1995) 0.95
Evaluation of a hepatocyte-entrapment hollow fiber bioreactor: a potential bioartificial liver. Biotechnol Bioeng (1993) 0.94
Structural requirements for the activity of an immunologically generated lipid chemotactic factor. Immunology (1980) 0.93
Cost effective strategy for a safe diagnosis of deep vein thrombosis at a district general hospital. Postgrad Med J (2003) 0.92
BRCA1 protein products: antibody specificity... Nat Genet (1996) 0.92
Preferential human eosinophil chemotactic activity of the platelet-activating factor (PAF) 1-0-hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine (AGEPC). J Clin Immunol (1987) 0.92
Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin Oncol (2001) 0.91
Alloantigen-specific cytotoxic clones bearing the alpha,beta T cell antigen receptor but not CD4 or CD8 molecules. J Immunol (1990) 0.91
Synthesis of platelet activating factor by ocular tissue from inflamed eyes. Arch Ophthalmol (1991) 0.91
Role of immunoglobulin G in platelet aggregation by viridans group streptococci. Infect Immun (1988) 0.91
Spatial distribution of mammalian cells grown on macroporous microcarriers with improved attachment kinetics. Biotechnol Prog (1993) 0.90
Regulation of human leukocyte function by lipoxygenase products of arachidonic acid. Contemp Top Immunobiol (1984) 0.89
V7, a novel leukocyte surface protein that participates in T cell activation. II. Molecular cloning and characterization of the V7 gene. J Immunol (1995) 0.88
Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs (2001) 0.88
Enhancement of human polymorphonuclear leukocyte adherence by the phospholipid mediator 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC). Am J Pathol (1983) 0.87
Late appearance of phospholipid platelet-activating factor and leukotriene B4 in human skin after repeated antigen challenge. J Allergy Clin Immunol (1989) 0.86
Identification of the platelet activating activity in rheumatoid synovial fluid as an intermediate molecular weight complex of IgG. J Immunol (1979) 0.86
V7, a novel leukocyte surface protein that participates in T cell activation. I. Tissue distribution and functional studies. J Immunol (1995) 0.85
Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers. Thromb Res (1987) 0.85
Hormone-refractory prostate cancer: an evolving standard of care. Semin Oncol (1999) 0.85
Undetectable serum prostate-specific antigen associated with metastatic prostate cancer: a case report and review of the literature. Am J Clin Oncol (1998) 0.85
Tumor necrosis factor release by human monocytes stimulated with platelet-activating factor. Lipids (1991) 0.84
Isolation of a platelet membrane protein which binds the platelet-activating factor 1-0-hexadecyl-2-acetyl-SN-glycero-3-phosphorylcholine. Immunology (1984) 0.84
Modulation of cytoplasmic calcium in human platelets by the phospholipid platelet-activating factor 1-O-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine. J Immunol (1985) 0.83
Bedside culture to confirm tuberculous pericarditis. Lancet (1992) 0.83
Extracorporeal application of a gel-entrapment, bioartificial liver: demonstration of drug metabolism and other biochemical functions. Cell Transplant (1994) 0.83
The extracellular and intracellular roles of hydroxy-eicosatetraenoic acids in the modulation of polymorphonuclear leukocyte and macrophage function. J Reticuloendothel Soc (1980) 0.82
Synergistic platelet activation by aggregates of IgG and the phospholipid platelet-activating factor 1-O-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine. J Clin Immunol (1986) 0.82
B4B, a novel growth-arrest gene, is expressed by a subset of progenitor/pre-B lymphocytes negative for cytoplasmic mu-chain. J Immunol (1996) 0.82
Modulation of human neutrophil and eosinophil polymorphonuclear leukocyte chemotaxis: an analytical review. Clin Immunol Immunopathol (1980) 0.81
Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate (CV-3988). Biochem Biophys Res Commun (1985) 0.81
Biological properties of dendritic cells: implications to their use in the treatment of cancer. Mol Med Today (1997) 0.80
Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis. Urology (2000) 0.80
Platelet-activating factor stimulates expression of IL-1 beta mRNA in THP-1 cells. Lipids (1991) 0.80
Development of a bioartificial liver employing xenogeneic hepatocytes. Cytotechnology (1997) 0.80
Platelet-activating activity in synovial fluids of patients with rheumatoid arthritis, juvenile rheumatoid arthritis, gout, and noninflammatory arthropathies. Arthritis Rheum (1980) 0.79
New parental cell lines for generating human hybridomas. J Immunol Methods (1992) 0.79
In vivo persistence of donor cells following adoptive transfer of allogeneic dendritic cells in HIV-infected patients. Cell Transplant (2000) 0.78
Potentiation of mitogen-induced human T-lymphocyte activation by retinoic acid. Cancer Res (1985) 0.78
Decay of the activating signal after platelet stimulation with 1-0-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine: changes in calcium permeability. Thromb Res (1985) 0.78
Entrapment of cultured pancreas islets in three-dimensional collagen matrices. Cell Transplant (1992) 0.78
Synergistic increases in IL-1 synthesis by the human monocytic cell line THP-1 treated with PAF and endotoxin. Cell Immunol (1990) 0.78
Anticancer drugs. Nature (1995) 0.78
A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer (1996) 0.77
Distinctive patterns of release of neuroendocrine peptides after nasal challenge of allergic subjects with ryegrass antigen. J Clin Immunol (1988) 0.77
Major histocompatibility complex class I-restricted presentation of protein antigens without prior intracellular processing. Scand J Immunol (2003) 0.77
Entrapment of hepatocyte spheroids in a hollow fiber bioreactor as a potential bioartificial liver. Tissue Eng (1995) 0.77
Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology (2001) 0.77
Immunogenic characterization of a tissue culture-derived vaccine that affords partial protection against avian coccidiosis. Poult Sci (1997) 0.76
Platelet-activating factor binding to human platelet membranes. Biotechnol Appl Biochem (1986) 0.76
Allergy and immunology: platelet-activating factor. West J Med (1989) 0.75
Bispecific Antibody MDX-210 for Treatment of Advanced Ovarian and Breast Cancer. Methods Mol Med (2001) 0.75
Lipid mediators of leukocyte function in immediate-type hypersensitivity reactions. Kroc Found Ser (1981) 0.75
Improved microscopic observation of mammalian cells on microcarriers by fluorescent staining. Cytotechnology (1991) 0.75
Selective activation of human monocytes by the platelet-activating factor analog 1-O-hexadecyl-2-O-methyl-sn-glycero-3-phosphorylcholine. J Immunol (1990) 0.75
Enhanced arachidonic acid lipoxygenation by K562 cells stimulated with 12-O-tetradecanoylphorbol-13-acetate. Cancer Res (1983) 0.75
Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1-infected and uninfected individuals. AIDS Res Hum Retroviruses (1997) 0.75
Third-generation aromatase inhibitors in the treatment of advanced breast cancer. Breast Cancer (2001) 0.75
Selective immobilization of human mononuclear phagocytes by benoxaprofen. Arthritis Rheum (1982) 0.75
Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer. Cytotherapy (2000) 0.75
New treatment strategies in advanced prostate cancer. Radiol Clin North Am (2000) 0.75
An update on prostate cancer research. Curr Opin Oncol (2000) 0.75
Tumor necrosis factor release by murine macrophages stimulated by the cytotoxic ether lipid 1-O-hexadecyl-2-O-methyl-SN-glycero-3-phosphorylcholine (ET-18-O-OCH3). Int J Immunopharmacol (1994) 0.75
Characterization of a novel cell surface molecule discovered on human peripheral blood lymphocytes achieved by a new, rapid technique for identification of molecules with transmembrane regions. Transplant Proc (1994) 0.75